XML 68 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statement Of Cash Flows (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Cash Flows from Operating Activities    
Net income $ 20,574 $ 22,278
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 8,158 7,922
Deferred income taxes 6,841 (681)
Provision for uncollectible accounts receivable 3,304 2,967
Amortization of discount on convertible notes 2,261 2,114
Stock option expense 1,309 1,491
Amortization of debt issuance costs 337 780
Noncash portion of long-term incentive compensation 373 612
Changes in operating assets and liabilities, excluding amounts acquired in business combinations:    
Increase in accounts receivable (27,700) (36,706)
Decrease in inventories 27 499
Increase in prepaid expenses (1,112) (1,092)
Decrease in accounts payable and other current liabilities (32,561) (698)
Increase in income taxes 5,322 10,139
Increase in other assets (1,069) (3,071)
Increase in other liabilities 3,080 3,282
Excess tax benefit on share-based compensation (1,399) (1,891)
Other sources 409 196
Net cash provided/(used) by operating activities (11,846) 8,141
Cash Flows from Investing Activities    
Capital expenditures (8,131) (5,406)
Business combinations, net of cash acquired (250)  
Other sources 29 78
Net cash used by investing activities (8,352) (5,328)
Cash Flows from Financing Activities    
Purchases of treasury stock (32,982)  
Dividends paid (3,303) (3,367)
Capital stock surrendered to pay taxes on stock-based compensation (2,916) (3,389)
Proceeds from exercise of stock options 13,193 10,168
Excess tax benefit on share-based compensation 1,399 1,891
Increase/(decrease) in cash overdrafts payable 369 (3,165)
Debt issuance costs   (1,107)
Other uses (501) (419)
Net cash provided/(used) by financing activities (24,741) 612
Increase/(Decrease) in Cash and Cash Equivalents (44,939) 3,425
Cash and cash equivalents at beginning of year 84,418 69,531
Cash and cash equivalents at end of period $ 39,479 $ 72,956